Breaking News
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Omeros (OMER) Announces Preliminary Data on MASP-3 Inhibitor

By Zacks Investment ResearchStock MarketsJun 10, 2021 03:53AM ET
Omeros (OMER) Announces Preliminary Data on MASP-3 Inhibitor
By Zacks Investment Research   |  Jun 10, 2021 03:53AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items

Commercial-stage biopharmaceutical Omeros (NASDAQ:OMER) Corporation OMER announced encouraging preliminary results from an early-stage study of its MASP-3 inhibitor, OMS906.

The ongoing phase I study is designed as a randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of intravenous (IV) and subcutaneous (SC) administration of OMS906 in healthy adult volunteers.

The phase I study design consists of both single- and multiple-ascending dose cohorts. OMS906, administered up to 5 mg/kg, was well tolerated at all IV and SC doses tested with no apparent safety signals. Single 3 mg/kg IV dose of OMS906 suppresses mature CFD below minimum detectable levels for 4 weeks. The single lowest SC dose of OMS906 suppresses mature CFD at or below minimum detectable levels for 4 weeks.

The dose-dependent PK/PD profile across all cohorts is favorable and supports low-dose, once-monthly or less frequent subcutaneous dosing.

We note that the study is ongoing with additional single- and multiple-dose cohorts to determine the pharmacologic dose range and optimal frequency for subcutaneous administration.

Omeros’ MASP-3 inhibitor program includes potent molecules selectively inhibiting mannan-binding lectin-associated serine protease-3 (MASP-3), the protein activator of the alternative pathway of complement (APC).

The preliminary data validate the function of MASP-3 — the key activator of the alternative pathway — as a regulator of CFD and support the potential of OMS906 as a safe and long-acting therapeutic for the treatment of alternative pathway-related diseases and disorders. The company intends to advance to a phase II study as soon as possible.

The development of the candidate will strengthen Omeros’ pipeline. The stock has increased 12.1% so far this year compared with the industry’s gain of 1.1%.

Zacks Investment Research
Zacks Investment Research
Image Source: Zacks Investment Research

The company’s lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement. The Biologics License Application (BLA) for narsoplimab is under priority review with the FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).

The company recently announced that the FDA will require additional time to review the BLA. The new target action date is Oct 17, 2021.

The BLA was accepted for filing in January 2021 under the FDA’s Priority Review program, with an action date of Jul 17, 2021. Omeros recently submitted a response to an FDA information request.

The agency has classified the response as a major amendment, which requires additional time to review as part of the ongoing BLA Priority Review. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, atypical hemolytic uremic syndrome and COVID-19.

Meanwhile, its marketed drug, Omidria, continues to gain market share in cataract surgery.

Omeros currently carries a Zacks Rank #4 (Sell).

A few better-ranked stocks in the healthcare sector include Repligen (NASDAQ:RGEN) Corp. RGEN, Cumberland Pharmaceuticals (NASDAQ:CPIX) Inc. CPIX and Xencor (NASDAQ:XNCR), Inc. XNCR, each carrying a Zacks Rank #2 (Buy).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Earnings estimates for Repligen for 2021 are up 40 cents.

Earnings estimates for Cumberland for 2021 are up 8 cents.

Loss estimates for Xencor have narrowed 81 cents.

Infrastructure Stock Boom to Sweep America

A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.

The only question is “Will you get into the right stocks early when their growth potential is greatest?”

Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.

Download FREE: How to Profit from Trillions on Spending for Infrastructure >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Cumberland Pharmaceuticals Inc. (CPIX): Free Stock Analysis Report

Repligen Corporation (RGEN): Free Stock Analysis Report

Omeros Corporation (OMER): Free Stock Analysis Report

Xencor, Inc. (XNCR): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research
Omeros (OMER) Announces Preliminary Data on MASP-3 Inhibitor

Related Articles

Craig Erlam
Record End To The Week By Craig Erlam - Jul 23, 2021

Optimism Builds Into Weekend Stock markets are ending the week on a positive note, with earnings continuing to surprise to the upside and COVID fears being brushed aside as the S&P...

Guy S. Ortmann, CMT
NDX Makes New Closing High By Guy S. Ortmann, CMT - Jul 23, 2021

The major equity indexes closed mixed yesterday, with negative internals on the NSYE and NASDAQ Composite as trading volumes declined on both exchanges from the prior session. The...

Omeros (OMER) Announces Preliminary Data on MASP-3 Inhibitor

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email